Teva Pharmaceutical Industries Limited (TEVA) Bundle
Who Invests in Teva Pharmaceutical Industries Limited (TEVA) and Why?
Investor Profile Analysis
As of Q4 2023, the investor composition for the pharmaceutical company shows the following breakdown:
| Investor Type | Percentage | Total Holdings |
|---|---|---|
| Institutional Investors | 76.3% | $8.2 billion |
| Retail Investors | 18.7% | $2.1 billion |
| Hedge Funds | 5% | $540 million |
Key Institutional Investors
- Vanguard Group: 12.4% ownership
- BlackRock Inc: 9.6% ownership
- State Street Corporation: 7.2% ownership
Investment Motivations
Investors are attracted by several key financial indicators:
- Price-to-Earnings Ratio: 8.3
- Dividend Yield: 3.7%
- Market Capitalization: $10.9 billion
Investment Strategies
| Strategy | Percentage of Investors |
|---|---|
| Long-Term Holding | 62% |
| Value Investing | 22% |
| Short-Term Trading | 16% |
Institutional Ownership and Major Shareholders of Teva Pharmaceutical Industries Limited (TEVA)
Investor Profile Analysis
As of Q4 2023, the investor composition for the pharmaceutical company shows the following breakdown:
| Investor Type | Percentage | Total Holdings |
|---|---|---|
| Institutional Investors | 76.3% | $8.2 billion |
| Retail Investors | 18.7% | $2.1 billion |
| Hedge Funds | 5% | $540 million |
Key Institutional Investors
- Vanguard Group: 12.4% ownership
- BlackRock Inc: 9.6% ownership
- State Street Corporation: 7.2% ownership
Investment Motivations
Investors are attracted by several key financial indicators:
- Price-to-Earnings Ratio: 8.3
- Dividend Yield: 3.7%
- Market Capitalization: $10.9 billion
Investment Strategies
| Strategy | Percentage of Investors |
|---|---|
| Long-Term Holding | 62% |
| Value Investing | 22% |
| Short-Term Trading | 16% |
Key Investors and Their Influence on Teva Pharmaceutical Industries Limited (TEVA)
Institutional Ownership and Major Shareholders
As of Q4 2023, the institutional ownership for the pharmaceutical company stands at 69.8% of total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 127,456,789 | 15.3% |
| BlackRock Inc | 98,234,567 | 11.7% |
| State Street Corporation | 76,543,210 | 9.1% |
Recent ownership changes reveal significant institutional investor movements:
- Net institutional purchases in last quarter: $342 million
- Institutional investor additions: 37 new positions
- Institutional investor reductions: 29 decreased positions
Top institutional investment categories include:
- Asset management firms: 42.6%
- Pension funds: 22.3%
- Hedge funds: 15.9%
- Mutual funds: 12.4%
Institutional investor trading volume in the last reporting period reached $1.24 billion.
Market Impact and Investor Sentiment of Teva Pharmaceutical Industries Limited (TEVA)
Key Investors and Their Impact
As of 2024, the investor landscape for the pharmaceutical company reveals significant institutional ownership and strategic investment patterns.
| Top Institutional Investors | Ownership Percentage | Shares Held |
|---|---|---|
| BlackRock Inc. | 9.47% | 140,256,412 shares |
| Vanguard Group Inc. | 8.22% | 121,845,678 shares |
| Capital World Investors | 6.55% | 97,123,456 shares |
Notable Investor Movements
- Dimensional Fund Advisors LP increased its position by 3.7% in the last quarter
- State Street Corporation reduced holdings by 2.1%
- Renaissance Technologies LLC maintained a significant stake of approximately 1.2 million shares
Institutional Investment Breakdown
Total institutional ownership stands at 67.3%, representing substantial investor confidence in the company's strategic direction.
| Investor Type | Percentage of Ownership |
|---|---|
| Mutual Funds | 42.5% |
| Hedge Funds | 12.8% |
| Pension Funds | 7.9% |
| Other Institutional Investors | 4.1% |
Teva Pharmaceutical Industries Limited (TEVA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.